Holen Sie sich die Stockscreener-App
45.10
2.15%
0.95
Vorhandelsmarkt:
45.36
0.26
+0.58%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol Myers, Takeda to pool data for AI-based drug discovery By Reuters - Investing.com
Judge denies motions by Bristol-Myers Squibb, State Street IM to dismiss PRT lawsuit - Pensions & Investments
Bristol Myers Squibb call volume above normal and directionally bullish - TipRanks
Multiple Modalities in the Oncology Market Size, Regional Growth and Trends - GlobeNewswire Inc.
Bristol-Myers Retirees’ Pension De-Risking Suit Moves Forward - Bloomberg Law News
Bristol Myers Squibb Company $BMY Position Cut by Capital Investment Advisors LLC - MarketBeat
JLL: Bristol Myers Squibb eyes sale, partial leaseback of 1.2 million sq. ft. Summit campus - Real Estate NJ
Bristol-Myers Squibb Company (BMY) Stock Analysis: 20% Upside Potential Amid Strong Dividend Yield - DirectorsTalk Interviews
Fort Washington Investment Advisors Inc. OH Acquires 7,095 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
KG&L Capital Management LLC Buys 39,136 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios - Insider Monkey
Perigon Wealth Management LLC Has $2.48 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Position Trimmed by TD Private Client Wealth LLC - MarketBeat
Trump's Drug Tariffs 'A Meaningful Commercial Hit' For Americans, Says AnalystEli Lilly (NYSE:LLY), Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Squibb discovers new TLR7 agonists - BioWorld MedTech
BMS adds discounted psoriasis drug to its DTC channel - pharmaphorum
Meyer Handelman Co. Has $24.44 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
BMS Expands Patient Options With Direct-to-Patient Platform - Dermatology Times
Bristol Myers Squibb to Offer More Than 80% off Sotyktu List Price - Managed Healthcare Executive
Bristol Myers Squibb leans into direct-to-consumer with telehealth launch, drug price drop - eMarketer
Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026 - Stocktwits
Bristol Myers to sell psoriasis drug at over 80% discount to some US patients - Reuters
BMS expands DTC offering with Sotyktu addition - Pharmaceutical Technology
PGIM Jennison Health Sciences Fund Sold its Position in Bristol-Myers Squibb Co. (BMY) in Q2 - Insider Monkey
Bristol Myers Squibb (BMY) Expands Discounted Drug Offerings - GuruFocus
Bristol Myers (BMY) Expands Direct Patient Access to Key Medicat - GuruFocus
Bristol Myers expands DTC offerings (BMY:NYSE) - Seeking Alpha
Bristol to Sell 80% Off Psoriasis Pill After Trump Demand - Bloomberg.com
Bristol Myers Squibb to offer steep discounts on Eliquis and Sotyktu - Investing.com Canada
Bristol Myers Squibb Builds on Eliquis (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu (deucravacitinib) - TradingView
80% Price Cut: Bristol Myers Squibb Makes Breakthrough Psoriasis Drug Sotyktu More Accessible - Stock Titan
Bristol Myers (BMY) Advances in Pulmonary Fibrosis Treatment - GuruFocus
Bristol to Sell Psoriasis Pill for 80% Off After Trump Demand - Bloomberg.com
FDA issues complete response letter for Bristol-Myers Squibb's hepatitis C drug daclatasvir - FirstWord Pharma
Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Bristol-Myers Squibb's Opdivo superior to chemotherapy in Phase III trial in advanced melanoma - FirstWord Pharma
Bristol-Myers Squibb (BMY) Faces Extended Losses Amid Analyst Op - GuruFocus
Pharma Is Pushing $200,000 Cancer Drugs When Cheaper Doses May Work - Bloomberg.com
BMS Phase III success with iberdomide - The Pharma Letter
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study - Yahoo Finance
Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients - Sahm
BMS eyes filings for myeloma 'celmod' iberdomide - pharmaphorum
When It Pays to Buy Stocks of Companies Clouded in Controversy - Morningstar
Bristol Myers Squibb’s new multiple myeloma therapy shows promise By Investing.com - Investing.com Nigeria
CHICAGO TRUST Co NA Sells 10,191 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Become a business supplier - Bristol Myers Squibb
Bristol-Myers Squibb Is Facing a Patent Cliff, but a Solid Pipeline Supports a Wide Moat - Morningstar
Bristol Myers Squibb Company $BMY Shares Sold by UMB Bank n.a. - MarketBeat
Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment - Yahoo Finance
Bristol Myers’ US/UK List Price Parity Plan For Cobenfy Leverages Trump’s MFN Concerns - insights.citeline.com
BMS’s Iberdomide Scores First Major Phase III Win - insights.citeline.com
Diversified Trust Co Purchases 9,105 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
BMS Adds To Big Pharma Pressure On UK With US Pricing For Cobenfy - insights.citeline.com
Bristol Myers says next-gen blood cancer drug hits goal in key study - BioPharma Dive
Bristol Myers Squibb at Bernstein Forum: Cell Therapy Insights - Investing.com
Bristol Myers Squibb’s new multiple myeloma therapy shows promise - Investing.com
Bristol Myers (BMY) Reports Promising Phase 3 Study Results for Iberdomide in RRMM - GuruFocus
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple M - BioSpace
Eaton Financial Holdings Company LLC Acquires New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Latest Company News - Investing.com UK
New Subcutaneous Formulation of OPDIVO® Receives Positive INESSS Recommendation for Multiple Tumour Types - PR Newswire Canada
Buy Bristol Myers Squibb Stock At $45? - Forbes
BMS says it will set Cobenfy's UK price the same as the US - pharmaphorum
1 Reason to Buy Bristol Myers Squibb Stock - The Motley Fool
3.40%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):